Tags

Type your tag names separated by a space and hit enter

Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial.
Eur Ann Allergy Clin Immunol. 2003 Jun; 35(6):212-6.EA

Abstract

OBJECTIVE

To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with osteoarthritis.

METHODS

In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects.

RESULTS

Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial.

CONCLUSION

Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect.

Authors+Show Affiliations

Yonsei Medical Clinic, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study

Language

eng

PubMed ID

12872680

Citation

Cho, Se Haeng, et al. "Clinical Efficacy and Safety of Lyprinol, a Patented Extract From New Zealand Green-lipped Mussel (Perna Canaliculus) in Patients With Osteoarthritis of the Hip and Knee: a Multicenter 2-month Clinical Trial." European Annals of Allergy and Clinical Immunology, vol. 35, no. 6, 2003, pp. 212-6.
Cho SH, Jung YB, Seong SC, et al. Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. Eur Ann Allergy Clin Immunol. 2003;35(6):212-6.
Cho, S. H., Jung, Y. B., Seong, S. C., Park, H. B., Byun, K. Y., Lee, D. C., Song, E. K., & Son, J. H. (2003). Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. European Annals of Allergy and Clinical Immunology, 35(6), 212-6.
Cho SH, et al. Clinical Efficacy and Safety of Lyprinol, a Patented Extract From New Zealand Green-lipped Mussel (Perna Canaliculus) in Patients With Osteoarthritis of the Hip and Knee: a Multicenter 2-month Clinical Trial. Eur Ann Allergy Clin Immunol. 2003;35(6):212-6. PubMed PMID: 12872680.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. AU - Cho,Se Haeng, AU - Jung,Young Bok, AU - Seong,Sang Cheol, AU - Park,Hyung Bin, AU - Byun,Ki Yong, AU - Lee,Dong Chul, AU - Song,Eun Kyoo, AU - Son,Jung Hwan, PY - 2003/7/23/pubmed PY - 2003/12/12/medline PY - 2003/7/23/entrez SP - 212 EP - 6 JF - European annals of allergy and clinical immunology JO - Eur Ann Allergy Clin Immunol VL - 35 IS - 6 N2 - OBJECTIVE: To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with osteoarthritis. METHODS: In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects. RESULTS: Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial. CONCLUSION: Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect. SN - 1764-1489 UR - https://www.unboundmedicine.com/medline/citation/12872680/Clinical_efficacy_and_safety_of_Lyprinol_a_patented_extract_from_New_Zealand_green_lipped_mussel__Perna_Canaliculus__in_patients_with_osteoarthritis_of_the_hip_and_knee:_a_multicenter_2_month_clinical_trial_ L2 - https://www.lens.org/lens/search?q=citation_id:12872680 DB - PRIME DP - Unbound Medicine ER -